一分钟看懂
这是一项关于结直肠癌的III 期研究，登记的药物或干预包括INCA33890；Placebo；Bevacizumab；FOLFOX，当前状态为招募中。登记地点显示中国北京、长沙、成都、重庆等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
INCA33890；Placebo；Bevacizumab；FOLFOX · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University First Hospital · 北京
- Beijing Friendship Hospital, Capital Medical University · 北京
- Xiangya Hospital Central South University · 长沙
- Sichuan Cancer Hospital · 成都
- Chongqing University Cancer Hospital · 重庆
- The First People'S Hospital of Foshan · 佛山
- Fujian Medical University Union Hospital · 福州
- Sun Yat-Sen University Cancer Center · 广州
- The Sixth Affiliated Hospital of Sun Yat-Sen University · 广州
- Zhujiang Hospital of Southern Medical University · 广州
- The Second Affiliated Hospital of Zhejiang University School of Medicine · 杭州
- Jinan Central Hospital · 济南
- Affiliated Hospital of Jining Medical University · 济宁
- The First Hospital of Lanzhou University · 兰州
- The First Affiliated Hospital of Nanchang University · 南昌
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Fudan University Shanghai Cancer Center · 上海
- Tianjin Medical University Cancer Institute Hospital · 天津
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology · 武汉
- Hubei Cancer Hospital · 武汉
公开的入选条件
- * Stage IV colorectal adenocarcinoma not amenable to curative resection.
- * No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment.
- * Measurable disease per RECIST v1.1.
- * ECOG performance status of 0 or 1.
- * Adequate organ function determined by laboratory results.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07284849；登记信息更新于 2026-09-15。